Merger Between Kyowa Hakko And Kirin Launches New Company
This article was originally published in PharmAsia News
Executive Summary
Oct. 1 marks the official start for Kyowa Hakko Kirin, a new company created by the merger of Kyowa Hakko and Kirin Pharmaceutical. Aiming to achieve ¥513 billion in sales by 2010 and become a top class specialty pharmaceutical company in the world, the merged company plans to accelerate research and development activities and launch two antibody products and two low-molecular chemical compounds each year. The new president Yuzuru Matsuda commented that to achieve the goals, the company has to maximum its unique strength in antibody technology. On the same day, Kyowa Hakko spun off its biochemical business, which became Kyowa Hokko Bio. (Click here for more - Japanese language